https://orcid.org/0000-0002-1610-0335
Figures & data
Table 1 Baseline Demographic and Disease Characteristics of Children with Moderate-to-Severe Asthma Who Did or Did Not Achieve 5% and 10% Improvements in Pre-Bronchodilator ppFEV1 from Baseline to Week 12
Figure 1 Reduction in severe asthma exacerbation rates during the VOYAGE Week 12 to 52 treatment period in children with moderate-to-severe asthma who did or did not achieve 5% and 10% improvements in pre-bronchodilator ppFEV1 from baseline by Week 12.
Notes: * P < 0.05, ** P < 0.01 vs matching placebo. †Reduction in relative risk vs matching placebo. Note: 11 patients with missing pre-bronchodilator ppFEV1 data at Week 12 are excluded from the analysis. All severe exacerbation events that occurred during Week 12 to 52 treatment period were included, regardless of whether the patient was on treatment.
Abbreviations: BD, bronchodilator; CI, confidence interval; ppFEV1, percent predicted forced expiratory volume in 1 second.
Figure 2 Change of pre-bronchodilator ppFEV1 over time in children with moderate-to-severe asthma who did or did not achieve 5% and 10% improvements in pre-bronchodilator ppFEV1 from baseline by Week 12.
Notes: *P < 0.05, **P < 0.01, ***P < 0.001 vs matching placebo. Eleven patients with missing pre-bronchodilator ppFEV1 data at Week 12 are excluded from the analysis.
Abbreviations: BD, bronchodilator; LS, least squares; ppFEV1, percent-predicted forced expiratory volume in 1 second; SE, standard error.
